Ultrasound Renal Denervation for Hypertension Resistant to a Triple Medication Pill:

> The Randomized Sham Controlled RADIANCE-HTN TRIO Trial

> > Ajay J. Kirtane, MD, SM @ajaykirtane



ACC.21

On behalf of Michel Azizi and the RADIANCE-HTN TRIO Investigators

Disclosures

 Dr. Kirtane reports Institutional funding to Columbia University and/or Cardiovascular Research Foundation from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, CathWorks, Siemens, Philips, ReCor Medical, Neurotronic. In addition to research grants, institutional funding includes fees paid to Columbia University and/or Cardiovascular Research Foundation for consulting/speaking. Personal: Travel Expenses/Meals from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, CathWorks, Siemens, Philips, ReCor Medical, Chiesi, OpSens, Zoll, and Regeneron


Background / Objective

- Endovascular renal denervation reduces blood pressure in patients with mild-moderate hypertension, but its blood pressure-lowering effect has not been previously demonstrated with confidence in patients with resistant hypertension
- The study objective was to investigate whether endovascular ultrasound renal denervation reduces daytime ambulatory systolic blood pressure in patients with hypertension resistant to a standardized fixed-dose triple medication pill

Paradise Ultrasound Renal Denervation System

- Ring of ablative energy (depth of 1-6 mm) to interrupt renal nerve traffic
- Arterial wall protected by water circulating through balloon
- 2-3 sonications lasting 7 seconds each are delivered to each main renal artery

Thermal Profile Ultrasonic Heating + Water Cooling





RADIANCE-HTN TRIO Design:

Blinded, Sham-Controlled, Powered to Demonstrate BP Lowering Effectiveness at 2M

Key Entry Criteria:

- Office BP ≥140/90 on 3+ anti-HTN meds
- Daytime ABP ≥135/85 on a fixed-dose, 3-drug combination pill
- Age 18-75 years
- No secondary hypertension aside from OSA
- No CV or cerebrovascular events within the prior 3M
- No Type I or uncontrolled Type II diabetes
- eGFR ≥40 mL/min/m²
- Eligible renal artery anatomy





*These subjects had a protocol-specified "0" value imputed for 2M change in ABPM for the Intent-to-Treat analysis

Clinical Characteristics

	RDN (N=69)	Sham (N=67)
Age (years)	52.3 ± 7.5	52.8 ± 9.1
Female sex	13/69 (19%)	14/67 (21%)
Race		
White	44/69 (64%)	50/67 (75%)
Black	14/69 (20%)	13/67 (19%)
Other / Unknown *	11/69 (16%)	4/67 (6%)
BMI - kg/m ²	32.8 ± 5.7	32.6 ± 5.4
Abdominal obesity +	54/66 (82%)	55/67 (82%)
eGFR - mL/min/1.73m ² *	86.0 ± 25.2	82.2 ± 19.2
eGFR<60 mL/min/1.73m ² *	8/67 (12%)	7/65 (11%)
Diabetes – Type 2	21/69 (30%)	17/67 (25%)
Sleep apnea	19/69 (28%)	11/67 (16%)
Prior Hospitalization for hypertensive crisis	15/69 (22%)	11/67 (16%)
Prior cardiovascular / cerebrovascular event	8/69 (12%)	9/67 (13%)
History of heart failure	1/69 (1%)	3/67 (4%)

* Two subjects in RDN and 2 subjects in Sham are missing race data. The four subjects with missing race data are not included in eGFR MDRD calculations. Site reported eGFR for these 4 subjects were all greater than 60mL/min/1.73 m² at baseline.


+ Abdominal obesity defined as a waist circumference greater than 102 cm for men and greater than 88 cm for women.

Screening Blood Pressures & Medications

	RDN (N=69)	Sham (N=67)
Blood Pressure		
Office SBP (mmHg)	161.9 ± 15.5	163.6 ± 16.8
Office DBP (mmHg)	105.1 ± 11.6	103.3 ± 12.7
Number of Anti-hypertensive Medications	4.0 ± 1.0	3.9 ± 1.1


100% 29% 22% 80% 29% 36% 60% 32% 36% 40% 39% 42% 0% RDN Sham 3 4 5 or more

Number of Medications at Screening



Classes of Anti-HTN Medications at Screening

Baseline Medications After 4 weeks of Triple Medication Combination Daily Pill



Baseline Blood Pressures:

After 4 weeks of Triple Medication Combination Daily Pill

	RDN (N=69)	Sham (N=67)
ABPM		
Daytime SBP (mmHg)	150.0 ± 11.9	151.1 ± 12.6
Daytime DBP (mmHg)	93.8 ± 7.7	94.6 ± 9.1
Nighttime SBP (mmHg)	134.4 ± 18.0	136.4 ± 18.6
Nighttime DBP (mmHg)	81.3 ± 10.7	81.3 ± 12.1
24-h SBP (mmHg)	143.9 ± 13.4	145.4 ± 14.0
24-h DBP (mmHg)	88.9 ± 8.2	89.5 ± 9.5
Home BP		
SBP (mmHg)	153.6 ± 16.2	153.4 ± 17.0
DBP (mmHg)	97.1 ± 10.9	96.9 ± 11.3
Office BP		
SBP (mmHg)	155.2 ± 16.8	155.1 ± 16.8
DBP (mmHg)	101.3 ± 11.7	99.6 ± 10.9

Procedural Details

	RDN (N=69)	Sham (N=67)
Procedure time (min)	83.0 [69.0, 99.0]	41.0 [33.0, 50.0]
Sedation		
Conscious Sedation	44/69 (64%)	41/67 (61%)
Monitored Anesthesia Care (e.g. propofol)	17/69 (25%)	16/67 (24%)
General Anesthesia	8/69 (12%)	10/67 (15%)
Contrast volume (cm ³)	176.9 ± 77.0	80.0 ± 40.1
Fluoroscopy time (min)	19.0 ± 11.5	4.1 ± 3.6
Treatment success (≥ 2 bilateral emissions)	67/69 (97%)*	NA
Total Number of Emissions	5.8 ± 1.2	NA
Left Main Renal	2.7 ± 0.5	NA
Right Main Renal	2.7 ± 0.5	NA
Subjects with Treated Accessory Renal Arteries	17/69 (25%)	NA
Total Emission Time (seconds)	40.7 ± 8.1	NA

Formal blinding assessments confirmed adequate blinding at discharge and 2-month follow-up

*1 subject had no treatments on one side; 1 subject had only one treatment on one side

Primary Efficacy Endpoint: Change in Daytime Ambulatory SBP at 2 Months

Intent-To-Treat Population Complete ABPM Population RDN Sham RDN Sham (N=69) (N=67) (N=63) (N=67) 0 0 -3.0 mm Hg -3.0 mm Hg mm Hg mm Hg -5 -5 Median Between Group Median Between Group Difference Difference -4.5 mmHg -5.8 mmHg (95% Cl, -9.7 to -1.6) (95% Cl, -8.5 to -0.3) -8.0 mm Hg P=0.022* P=0.005* -10 -10 -9.7 mm Hg IQR: IQR: IQR: IQR: -10.3 to 1.8 -16.4 to 0.0 -17.1 to -1.4 -10.3 to 1.8 -15 -15 N=6 RDN w/missing data set to 0 N=4 Sham that met escape set to 0 N=4 Sham that met escape set to 0


*Baseline-adjusted ANCOVA on the ranks due to non-normality of distribution

ABPM profiles at Baseline and 2 Months


ITT Population (Imputed Missing and Escape)

Population

(Imputed Escape)




Individual Patient Responses and % patients with controlled BP: Change in Daytime Ambulatory SBP at 2 Months (Complete ABPM Population)



Change in Office and Home SBP at 2 Months

Office SBP



*Baseline-adjusted ANCOVA on the ranks due to non-normality of distribution


Home SBP

Antihypertensive Medication Changes (ITT Population)

Medication Changes	RDN (N=69)	Sham (N=67)	P-value
Additional meds at 2M *	3/69 (4%)	8/67 (12%)	0.10
Protocol defined criteria	0/69 (0%)	4/67 (6%)	0.056
Physician decision/patient preference	3/69 (4%)	4/67 (6%)	0.72
Reduction in meds at 2M	2/69 (3%)	2/67 (3%)	1.0


*2 pts of the RDN group were on 25mg spironolactone; 7 pts of the sham group were on spironolactone (2 on 12.5mg, 4 on 25mg and 1 on 50mg)

Medication Adherence as Measured by Urine HPLC-MS/MS




75% of subjects were fully adherent at both Baseline and 2 months

Subgroup Analysis: Between Group Difference in 2-month Change in Daytime Ambulatory SBP



Median Difference in mmHg (95% CI)

eGFR at 2 Months (Matched data at baseline and 2 months)



Note: Two subjects in the renal denervation group and two subjects in the sham group are missing race data and therefore not included in the eGFR calculations.

Major Adverse Events

Major Adverse Events	RDN (N=69)	Sham (N=67)
30-Day Major Adverse Events		
Death	1 (1%) ¹	0 (0%)
End stage renal disease, the need for permanent renal replacement therapy	0 (0%)	0 (0%)
Doubling of plasma creatinine	1 (1%) ²	0 (0%)
Embolic event resulting in end organ damage	0 (0%)	0 (0%)
Renal artery complication requiring intervention	0 (0%)	0 (0%)
Major access site complications requiring intervention	1 (1%) ³	0 (0%)
Hypertensive emergency resulting in hospitalization	0 (0%)	0 (0%)
Other Major Adverse Events Measured Through 2 Months		
New onset renal artery stenosis of greater than 70%	0 (0%)	0 (0%)

¹ Sudden death unrelated to device or procedure 21 days post-procedure

² Transient acute renal injury 25 days post-procedure associated with spironolactone use and resolved upon discontinuation of spironolactone

³ Femoral access site pseudoaneurysm post-procedure resolved with thrombin injection

Limitations

- Additional follow-up will be required to determine whether the blood pressure lowering effect of ultrasound renal denervation remains safe and durable over time, especially when patients who remain uncontrolled receive additional antihypertensive medications, including the aldosterone antagonist spironolactone
- Without robust pre-procedural predictors of responsiveness and the absence of an intraprocedural marker of denervation success, between-patient variability will continue to be observed

Conclusions

- In patients with hypertension resistant to guideline-recommended triple combination therapy in a single pill, ultrasound based RDN was associated with a reduction of 8.0 mmHg in daytime ambulatory SBP (a 4.5 mmHg greater decrease than a sham procedure)
- The greater BP lowering effect of RDN vs. sham was consistent for 24h, nighttime, and office SBP
- These results are concordant with those of RADIANCE-HTN SOLO (patients with mild-to-moderate hypertension), confirming that ultrasound RDN can lower BP across a spectrum of hypertension
- Longer-term assessments for efficacy as well as safety are ongoing

Thank you to all the RADIANCE-HTN TRIO Study Centers!

Europe (N=25) United States (N=28) St. Barts Health NHS Trust – M. Saxena Deborah Heart & Lung Center – K. Sanghvi Hôpital Saint-André - CHU Bordeaux – P. Gosse Ochsner Heart and Vascular Institute – J.P. Reilly Royal Bournemouth Hospital – T. Levy Vanderbilt University Medical Center – P. Fong Hôpital Européen Georges-Pompidou – M. Azizi Stamford Hospital – D. Hsi Cliniques Universitaires Saint-Luc – A. Persu NYU Langone Medical Center – S. Bangalore University Clinic Dusseldorf – L.C. Rump Medical University of South Carolina – T. Todoran Emory University – C. Devireddy Clinique Pasteur / GCVI – Toulouse – A. Pathak Erasmus MC Rotterdam – J. Daemen Cedars-Sinai Medical Center – F. Rader Hôpital de la Croix Rousse, Lyon – P. Lantelme University of Utah Medical Center – J. Abraham Royal Devon and Exeter NHS Foundation Trust – A.S.P. Sharp University of Alabama – D. Calhoun Institute of Cardiology, Warsaw - A. Witkowski Columbia University Medical Center – A.J. Kirtane Sana Kliniken Lübeck GmbH - J. Weil Massachusetts General Hospital – J. Garasic University Clinic of Saarland, Homburg – F. Mahfoud The Cardiac and Vascular Institute, Gainesville – M. Khuddus The Essex Cardiothoracic Centre – J. Sayer Minneapolis Heart Institute Foundation – Y. Wang Drexel University – J. Goldman Leipzig Heart Center – P. Lurz Medical University of Gdansk – D. Hering The Heart Hospital Baylor Plano – S. Potluri Conquest Hospital, East Sussex NHS Trust - R. Gerber The Brigham and Women's Hospital – N.D.L. Fisher University Clinic Erlangen – R.E. Schmieder University of North Carolina – R. Stouffer Maastricht University Hospital – A. Kroon University Hospitals Cleveland Medical Center - D. Zidar Hammersmith Hospital, Imperial College NHS Trust – J. Davies Renown Institute for Heart & Vascular Health – M.J. Bloch Katholisches Klinikum Mainz – S. Genth-Zotz University of Pennsylvania – D. Cohen

Franciscan Health Indianapolis - A.R. Chugh

Bridgeport Hospital - R. Fishman Baptist Health Lexington - M. Jones Munson Medical Center - T. Adams

Cleveland Clinic - C. Bajzer

Sutter Medical Center, Sacramento – P. Huang

Southern Illinois University School of Medicine – J. Flack

CHRU Lille - P. Delsart Nottingham University Hospitals NHS Trust – S. Jadhav Freiburg University – C. von zur Mühlen

University Medical Center Utrecht – P. Blankestijn